From the investor presentation on 1/9/2016 page 9
Bringing NovoSorb BTM to market
o Regulatory paths through clinical trials
1. Achieve 510(k) approval for use in Surgical Wounds anticipated January 2016
2. Establish Clinical trials for FDA PMA approval in Burns, February 2016 ; • Contingent on BARDA funding.
3. CE Mark trials commenced in Australia & France o CE Mark anticipated Mid-2017
4. Prioritising jurisdictions where access can be achieved with existing data.
o Commercial execution
o We will initiate direct sales to establish market penetration where we have regulatory approval
o Establish commercial partnerships or licence agreements with KPIs around sales performance and revenue generation
We anticipate commercial sales in US Market Early 2016 once 510(k) approved
I think the distribution deal will be sooner rather then later.
- Forums
- ASX - By Stock
- Waiting for licencing agreement to be announced
From the investor presentation on 1/9/2016 page 9 Bringing...
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PNV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.52 |
Change
0.165(7.02%) |
Mkt cap ! $1.692B |
Open | High | Low | Value | Volume |
$2.38 | $2.52 | $2.38 | $2.356M | 957.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 25566 | $2.51 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.52 | 54260 | 18 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
38 | 53323 | 2.500 |
24 | 29187 | 2.490 |
15 | 27708 | 2.480 |
11 | 18966 | 2.470 |
11 | 74030 | 2.460 |
Price($) | Vol. | No. |
---|---|---|
2.510 | 8182 | 5 |
2.520 | 40160 | 15 |
2.530 | 117580 | 11 |
2.540 | 71955 | 14 |
2.550 | 207537 | 11 |
Last trade - 11.34am 10/09/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |